Spots Global Cancer Trial Database for bone marrow transplant
Every month we try and update this database with for bone marrow transplant cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | NCT00325416 | Multiple Myelom... | melphalan topotecan (TPT) Autologous Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 | NCT01044069 | Leukemia Acute Lymphobla... | gene-modified T... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN) | NCT02895841 | Pain | SMART app weara... | 8 Years - 80 Years | Duke University | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | NCT03795597 | Multiple Myelom... | Carfilzomib Busulfan IV Melphalan IV | 18 Years - | Loyola University | |
| Busulfan, Melphalan, Escalating Carfilzomib Conditioning Auto Stem Cell Transplantation for Multiple Myeloma (MM) | NCT03795597 | Multiple Myelom... | Carfilzomib Busulfan IV Melphalan IV | 18 Years - | Loyola University | |
| Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients | NCT00386373 | Leukemia | Imatinib Mesyla... | 16 Years - | M.D. Anderson Cancer Center | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive | NCT05603156 | Ph+ ALL Bone Marrow Tra... Minimal Residua... | the usage of Ol... | 18 Years - | Institute of Hematology & Blood Diseases Hospital, China | |
| A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis | NCT02057289 | Immunocompromis... Bone Marrow Tra... Cancer | Micafungin | 6 Months - 10 Years | Children's Hospital Medical Center, Cincinnati | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Effects of Digital Stories Intervention on Psychosocial Well-being | NCT03654599 | Bone Marrow Tra... Information Dis... Hematopoietic S... Psychosocial He... Depression Anxiety Stress Narrative | Baseline Survey... Digital Stories... Information Con... | 18 Years - | Arizona State University | |
| Massage for Pediatric Oncology | NCT00843180 | Bone Marrow Tra... Distress | massage | 5 Years - 18 Years | University of California, San Francisco | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant Population | NCT04025190 | Anxiety Depression | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| Giving Gene Marked EBV Specific T-Cells to Patients Receiving a BMT for Relapsed EBV-Positive Hodgkin Disease | NCT00058773 | Hodgkin Disease Non-Hodgkins Ly... | Infusion of EBV... | - | Baylor College of Medicine | |
| Study of Melphalan and Topotecan (MT) Followed by Autologous Stem Cell Rescue in Patients With Multiple Myeloma. | NCT00325416 | Multiple Myelom... | melphalan topotecan (TPT) Autologous Stem... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT) | NCT01379209 | Graft Versus Ho... | RGI-2001 Calcineurin Inh... Allogeneic Hema... Conditioning Re... Allogeneic Bone... Methotrexate Mofetil Mycophe... sirolimus | 18 Years - | Regimmune Corporation | |
| HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 | NCT04975698 | HIV Associated ... | HST-NEETs Bone Marrow Tra... | 15 Years - | National Heart, Lung, and Blood Institute (NHLBI) | |
| Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | NCT00025662 | Graft vs Host D... Myelodysplastic... Leukemia Leukemia, Myelo... Leukemia, Myelo... Leukemia, Lymph... Lymphoma Lymphoma, Mantl... Lymphoma, Non-H... Hodgkin Disease | RFT5-SMPT-dgA Isolex system | 18 Years - 75 Years | National Institutes of Health Clinical Center (CC) | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Effectiveness of Lay Navigators in Meeting Cancer Patients' Non-Clinical Needs: A Pilot Study | NCT03245788 | Breast Cancer Gynecologic Can... Neck Cancer Head and Neck C... Gastrointestina... Thoracic Cancer Cutaneous Tumor Urologic Cancer Neurologic Canc... Lymphoma Sarcoma Bone Marrow Tra... | Lay Navigation | 18 Years - | Stanford University | |
| Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia | NCT02665065 | Acute Myeloid L... Leukemia, Acute... Myeloid Leukemi... Leukemia, Myelo... Acute Myelogeno... Leukemia, Acute... Myelogenous Leu... AML Bone Marrow Tra... | Iomab-B Conventional Ca... HCT | 55 Years - | Actinium Pharmaceuticals | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | NCT00677859 | Hematologic Mal... | MultiStem® MultiStem® | 18 Years - 65 Years | Healios K.K. | |
| HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903 | NCT04975698 | HIV Associated ... | HST-NEETs Bone Marrow Tra... | 15 Years - | National Heart, Lung, and Blood Institute (NHLBI) | |
| Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide | NCT03088709 | Acute Myeloid L... Acute Lymphocyt... Myelodysplastic... Non-hodgkin Lym... Chronic Lymphoc... | Cyclophosphamid... Tacrolimus Mycophenolate m... Haploidentical ... | 16 Years - 90 Years | Loyola University | |
| A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) Followed by Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Relapsed and Refractory Hematologic Malignancies | NCT05201183 | Acute Myeloid L... Chronic Myeloid... Acute Lymphocyt... Myelodysplastic... | Fludarabine + T... | 18 Years - | Indiana University | |
| Phase I Study of Lenalidomide in Patients With Acute Leukemia | NCT01615042 | Acute Leukemia | Lenalidomide | 18 Years - 80 Years | University of California, Davis | |
| IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
| Pilot Study of Non-Myeloablative, HLA-Matched Allogeneic Stem Cell Transplantation for Pediatric Hematopoietic Malignancies | NCT00013533 | Hodgkin Lymphom... Lymphocytic Leu... Mixed Cell Leuk... Myelodysplastic... Non Hodgkin's L... CML ALL AML Lymphoma | Stem cell trans... | 4 Years - 20 Years | National Institutes of Health Clinical Center (CC) | |
| Allogeneic Stem Cell Transplantation in Chronic Myeloid Leukemia Failing TKIs Therapy | NCT02638467 | Leukemia Myelogenous Chronic BCR-ABL Positiv... | Bosutinib Bone Marrow Tra... Bone Marrow cel... | 18 Years - 70 Years | University of Milano Bicocca | |
| Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation | NCT04395222 | Hematologic Mal... Bone Marrow Tra... | Tocilizumab Fludarabine Melphalan Anti-thymocyte ... Total Body Irra... | 18 Years - | Weill Medical College of Cornell University | |
| Effect of Mobile Application on Supportive Care Needs and Quality of Life Patients Undergoing Hematopoietic Stem Cell Transplantation | NCT05609227 | Hematologic Mal... Patient Educati... | mobile applicat... | 18 Years - | Baskent University | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies | NCT00566696 | Leukemia, Acute... Leukemia, Myelo... Leukemia, Myelo... Juvenile Myelom... Hemoglobinuria,... Hodgkin Lymphom... Lymphoma, Non-H... Myelodysplastic... | CliniMACS Stem cell trans... Fludarabine Thioplex® L-phenylalanine... Mycophenolate m... Rituxan™ Alemtuzumab Cyclophosphamid... Anti-thymocyte ... G-CSF Muromonab | - 21 Years | St. Jude Children's Research Hospital | |
| Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | NCT01342289 | Hodgkin's Lymph... Leukemia Myelodysplastic... Multiple Myelom... Non Hodgkin's L... | Cyclophosphamid... Fludarabine Total body irra... Mycophenolate M... Tacrolimus 60 Tacrolimus 90 Tacrolimus 120 Bone marrow tra... | 6 Months - 75 Years | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| Blood and Marrow Transplant Clinical Research Network | NCT00023530 | Bone Marrow Tra... Blood Disease Hematopoietic S... Leukemia Multiple Myelom... Myelodysplastic... Graft vs Host D... | fluconazole voriconazole bone marrow tra... thalidomide dexamethasone | 2 Years - | National Heart, Lung, and Blood Institute (NHLBI) | |
| Chemotherapy Toxicity Reduction Via Urea Cycle Support | NCT00223730 | Cancer | Citrulline Placebo | 13 Years - 65 Years | Vanderbilt University | |
| Relationship Between Personality and Coping Styles in Bone Marrow Transplant Candidates | NCT00048256 | Adaptation, Psy... Bone Marrow Tra... | - | National Institutes of Health Clinical Center (CC) | ||
| Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients | NCT03030248 | Clostridium Dif... Hematologic Dis... Bone Marrow Tra... Oncologic Disor... | Vancomycin Oral... Placebo Oral Ca... | 18 Years - | Medical College of Wisconsin | |
| Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey. | NCT05352789 | Haematological ... Bone Marrow Tra... Stem Cell Trans... Nutrition Aspec... Nutritional and... Exercise Interv... Prehabilitation | Non validated S... | 18 Years - | Nottingham University Hospitals NHS Trust | |
| A Pharmacokinetic Study of Pediatric Micafungin Prophylaxis | NCT02057289 | Immunocompromis... Bone Marrow Tra... Cancer | Micafungin | 6 Months - 10 Years | Children's Hospital Medical Center, Cincinnati | |
| Massage for Pediatric Oncology | NCT00843180 | Bone Marrow Tra... Distress | massage | 5 Years - 18 Years | University of California, San Francisco | |
| Blood and Marrow Transplant Clinical Research Network | NCT00023530 | Bone Marrow Tra... Blood Disease Hematopoietic S... Leukemia Multiple Myelom... Myelodysplastic... Graft vs Host D... | fluconazole voriconazole bone marrow tra... thalidomide dexamethasone | 2 Years - | National Heart, Lung, and Blood Institute (NHLBI) | |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| SCRI Tissue Testing Registry | NCT00965861 | Melanoma Myelodysplastic... Multiple Myelom... Lymphoma | Tissue Registry... | 18 Years - | SCRI Development Innovations, LLC | |
| Chemotherapy in Treating Patients With Myelodysplastic Syndrome Before Donor Stem Cell Transplant | NCT01812252 | Chronic Myelomo... de Novo Myelody... Myelodysplastic... Secondary Myelo... | Azacitidine (AZ... Decitabine Quality-of-Life... | 18 Years - | Fred Hutchinson Cancer Center | |
| PR1-Specific Cytotoxic T-Lymphocyte Infusion With Recurrent Chronic Myelogenous Leukemia (CML) After Allogeneic Hematopoietic Transplantation | NCT00866346 | Chronic Myeloge... | PR1-primed lymp... | - | M.D. Anderson Cancer Center | |
| Oral Posaconazole Three Times Per Day vs Weekly High Dose Amphotericin B Lipid Complex (ABLC) | NCT00750737 | Invasive Fungal... Hematologic Mal... | Posaconazole ABLC | 18 Years - | M.D. Anderson Cancer Center | |
| Safety Study of MultiStem® in Patients With Acute Leukemia, Chronic Myeloid Leukemia, or Myelodysplasia | NCT00677859 | Hematologic Mal... | MultiStem® MultiStem® | 18 Years - 65 Years | Healios K.K. | |
| Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment | NCT01548573 | Multiple Myelom... | Dexamethasone Tandem autologo... Cisplatin Doxorubicin Cyclophosphamid... Etoposide Bortezomib Thalidomide Melphalan | 18 Years - 80 Years | University of Iowa | |
| Assessing the Feasibility of Screening and Treating Anxiety and Depression in the Bone Marrow Transplant Population | NCT04025190 | Anxiety Depression | 18 Years - | UNC Lineberger Comprehensive Cancer Center | ||
| T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant | NCT00048464 | Multiple Myelom... | Infusion of Act... | 18 Years - 70 Years | Xcyte Therapies | |
| Nutrition and Metabolic Prehabilitation in HSCT Patients UK and ROI. BSBMT Multi-centre Survey. | NCT05352789 | Haematological ... Bone Marrow Tra... Stem Cell Trans... Nutrition Aspec... Nutritional and... Exercise Interv... Prehabilitation | Non validated S... | 18 Years - | Nottingham University Hospitals NHS Trust | |
| HSCT for Patients With Fanconi Anemia Using Risk-Adjusted Chemotherapy | NCT02143830 | Fanconi Anemia Severe Marrow F... Myelodysplastic... Acute Myelogeno... | Busulfan Cyclophosphamid... Fludarabine rabbit ATG G-CSF Peripheral bloo... | 3 Months - | Children's Hospital Medical Center, Cincinnati | |
| Chemotherapy Toxicity Reduction Via Urea Cycle Support | NCT00223730 | Cancer | Citrulline Placebo | 13 Years - 65 Years | Vanderbilt University | |
| Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HCT) | NCT00285259 | Acute Lymphobla... Chronic Myeloge... Acute Myelogeno... Hodgkin's Lymph... Non-Hodgkin's L... Myelodysplastic... | VCL-CB01 Phosphate-buffe... | 18 Years - 65 Years | Astellas Pharma Inc | |
| Geriatric Communication Skills Training Program for Oncology Clinicians | NCT03530969 | GI Cancer Lymphoma GU Cancer Bone Marrow Tra... | Self-Efficacy A... UCLA Geriatrics... Course Evaluati... The Consultatio... Consumer Assess... Patient activat... | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Cryopreserved MMUD BM With PTCy for Hematologic Malignancies | NCT05170828 | Acute Leukemia Myelodysplastic... T-lymphoblastic... Acute Lymphocyt... Acute Myeloid L... Acute Biphenoty... Acute Undiffere... | Cyclophosphamid... Fludarabine Total Body Irra... Busulfan Mesna Sirolimus Mycophenolate M... Filgrastim Cyclophosphamid... Bone Marrow Tra... | 18 Years - 70 Years | Ossium Health, Inc. | |
| The Effects of Heart Rate Variability Biofeedback Training on Hematopoietic Cell Transplantation Patients | NCT04275830 | Hematopoietic S... Bone Marrow Tra... Heart Rate Vari... Autonomic Nervo... Stress Mood Psychological D... Emotion Regulat... Communication R... Narrative | Baseline Survey... Heart rate vari... Heart rate vari... | 18 Years - | Arizona State University | |
| Comparing Autologous Peripheral Blood Stem Cell to Bone Marrow Transplantation for Recurrent Non-Hodgkin's Lymphoma | NCT00574626 | Lymphoma | PBSCT Bone Marrow Tra... | 16 Years - 65 Years | University of Nebraska | |
| CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies | NCT04282174 | Hematologic Dis... Hematologic Mal... Acute Lymphobla... Acute Myeloid L... Chronic Myeloge... Chronic Lymphoc... | CliniMACS Bone Marrow Tra... Hyperfractionat... Thiotepa Cyclophosphamid... Busulfan Melphalan Fludarabine | - 74 Years | Baptist Health South Florida | |
| Effects of Digital Stories Intervention on Psychosocial Well-being | NCT03654599 | Bone Marrow Tra... Information Dis... Hematopoietic S... Psychosocial He... Depression Anxiety Stress Narrative | Baseline Survey... Digital Stories... Information Con... | 18 Years - | Arizona State University | |
| Facilitating Parent Adaptation to Pediatric Transplant: The P-SCIP Trial | NCT00939380 | Childhood Cance... | Behavioral inte... CD-ROM DVD and pamphle... Respite care | 18 Years - | Rutgers, The State University of New Jersey | |
| A Phase I Trial of Alloreactive Cell Infusion Following Transplantation of Haplotype Cells in Patients With Myeloid Malignancies | NCT00569179 | Leukemia, Myelo... Leukemia, Lymph... Myelodysplastic... Leukemia, Myelo... | CliniMACS CD34 ... | 18 Years - 65 Years | Indiana University | |
| Mindfulness Meditation in Bone Marrow Transplantation | NCT00165282 | Hematologic Mal... Bone Marrow Tra... Stem Cell Trans... | Mindfulness tra... Nurse education | 21 Years - | Emory University | |
| PRO#0118: Decitabine Plus Mini Flu-Bu | NCT01455506 | Acute Myeloid L... Myelodysplastic... | Decitabine plus... | 45 Years - 80 Years | Hackensack Meridian Health | |
| Combined Bone Marrow and Kidney Transplant for Multiple Myeloma With Kidney Failure | NCT00062621 | Kidney Failure,... Multiple Myelom... | Combined bone m... | 18 Years - 65 Years | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies | NCT00143559 | Leukemia Acute Lymphobla... Acute Myeloid L... Chronic Myeloid... Juvenile Myelom... Myelodysplastic... Paroxysmal Noct... Hodgkin's Lymph... Non-Hodgkin Lym... | Systematic chem... Allogeneic stem... Miltenyi CliniM... | 2 Years - 21 Years | St. Jude Children's Research Hospital | |
| Post Transplant Donor Lymphocyte Infusion | NCT00167180 | Leukemia, Myelo... Lymphomas Multiple Myelom... Myelodysplastic... Leukemia, Lymph... Leukemia, Lymph... AML | Donor Lymphocyt... Induction Chemo... | 1 Year - 70 Years | Masonic Cancer Center, University of Minnesota | |
| IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. | |
| Safety and Early Efficacy Study of TBX-2400 in Patients With AML or Myelofibrosis | NCT04709458 | Myelofibrosis Acute Myelogeno... | TBX-2400 | 18 Years - | Taiga Biotechnologies, Inc. | |
| Patient-Empowered Mobile Technology in Hospitalized Patients (TRU-PAIN) | NCT02895841 | Pain | SMART app weara... | 8 Years - 80 Years | Duke University | |
| Infusion of Allogeneic CD19-Specific T Cells From Peripheral Blood | NCT01497184 | Leukemia Lymphoma | HSCT DLI | 1 Year - 65 Years | M.D. Anderson Cancer Center | |
| A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance | NCT03114865 | Acute Lymphobla... B-cell Non Hodg... Pre B-Cell Acut... | Blinatumomab 9u... Blinatumomab 28... Blinatumomab Dexamethasone | 18 Years - | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | |
| IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients | NCT01009840 | Multiple Myelom... | IV busulfan bortezomib Autologous Hema... | 18 Years - 75 Years | Otsuka Pharmaceutical Development & Commercialization, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
